ALTASCIENCES
9.12.2021 17:02:06 CET | Business Wire | Press release
Altasciences is pleased to have been chosen by XORTX Therapeutics, Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19. XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors are aimed at reducing uric acid levels in order to slow the progression of the genetic disorder ADPKD, and protect against acute kidney injury following COVID-19 infection.
The first of several clinical trials to characterize XORTX’s novel, proprietary formulations of xanthine oxidase inhibitors, its purpose is to determine whether the increased bioavailability of oxypurinol demonstrated for this formulation in preclinical studies will be replicated in humans.
Dr. Allen Davidoff, President and CEO stated, “XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors. This study marks the first of several clinical trials planned for the next year and an exciting opportunity to advance our kidney disease programs through preliminary characterization, followed by late stage registration trials. ”
“With a pressing need for better therapeutic options and a global prevalence of kidney disease, we are proud to partner with XORTX for such an important study. We look forward to supporting this innovative company in their goal of bringing a valuable new treatment to the next stage, and getting better drugs to the people who need them, faster, ” stated Ingrid Holmes, Vice President, Global Clinical Operations at Altasciences.
Altasciences offers a seamless drug development solution that allows sponsors to work with a single, integrated CRO/CDMO in support of early-phase research, from lead candidate selection to preclinical testing to clinical proof of concept in the most time- and cost-efficient way possible.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services . For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing , clinical pharmacology and proof of concept , bioanalysis , program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209005134/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp and Elastio Announce Partnership to Deliver Defense-in-Depth Ransomware Resilience24.3.2026 13:00:00 CET | Press release
Robust cyber resilience requires both perimeter defenses and built-in security at the storage layer NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Elastio are helping enterprises enhance their cyber resilience with a layered defense that extends from production storage into recovery data. Security teams must be ready to address threats at every layer of their technology stack, including ransomware that moved quietly through production before it was caught that now lives inside snapshots and backups. Advanced ransomware is engineered to evade prevention tools, moving quietly through production, staying below detection thresholds, reaching backup data before any alert is triggered. "As we migrated our infrastructure, ensuring we had the right level of backup security and assurance was non-negotiable,” Marc Crudgington, VP IT Infrastructure and CISO, Crane WW Logistics. “Elastio provided continuous inspection of our backups from day one - giving us confidence in
NetApp and Commvault Advance Cyber Resilience with Strategic Alliance24.3.2026 13:00:00 CET | Press release
Joint unified cyber resilience solution delivers data security and rapid recovery across hybrid environments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Commvault (NASDAQ: CVLT), a leader in unified resilience at enterprise scale, today announced a strategic alliance to deliver a powerful, integrated solution for enterprise data protection and cyber resilience. The unified solution enables resilience, security, and rapid recovery for customers across on-premises and cloud environments, giving organizations confidence that their data is always available, immutable, and recoverable. “This alliance reinforces NetApp and Commvault’s leadership in the rapidly evolving cyber resilience and data protection market,” said Dallas Olson, Chief Commercial Officer at NetApp. “Together we’re helping customers make their infrastructure intelligent and secure so they have the confidence that their data is always available, protected, and recoverable—no matter where it live
SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0”24.3.2026 13:00:00 CET | Press release
Pioneering the “Performance Medicine” category for full-scale entry into the longevity market — targeting a global market projected to reach $2 trillion by 2035 SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced “SBC Wellness 2.0,” a new wellness and longevity platform that combines aesthetic healthcare, preventative care, and data-driven health management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323000188/en/ SBC Medical Announces Next-Generation Wellness Strategy “SBC Wellness 2.0” The initiative positions SBC Medical to participate in the fast-growing longevity market, which is projected to reach approximately $800 billion in 2025* and expand to approximately $2 trillion by 2035, with a compound annual growth rate exceeding 10% from 2026 to 2035. Th
Andy Walsky of ExaGrid Honored as A 2026 CRN EMEA Channel Leader24.3.2026 13:00:00 CET | Press release
ExaGrid®, the leader in Tiered Backup Storage, today announced that CRN UK—a brand of The Channel Company—has selected Andy Walsky, VP of EMEA & APAC Sales, for inclusion on the prestigious 2026 CRN® Channel Leaders EMEA list. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260324173870/en/ ExaGrid works with resellers and distributors worldwide. The ExaGrid channel programs are designed to be easy for partners, with support from the ExaGrid sales team and without milestone commitments. ExaGrid is known for having a Tiered Backup Storage system that “just works,” is not oversold or undersized, and provides its customers with the best customer support in the industry with an assigned level 2 technical support engineer, ensuring that partners’ customers are well ta
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights24.3.2026 12:30:00 CET | Press release
COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profileAcross three large trials in TRD, including two positive Phase 3 studies, COMP360’s differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved beforeCompass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4Compass is rapidly advancing commercial readiness plans and expects COMP360 will fit seamlessly across diverse healthcare settings at launchPhase 2b/3 trial in PTSD initiating, following FDA acceptance of IND applicationSuccessful $150 million financing in February and exercise of $200 million in warrants extends cash runway into 2028 Compass Pathways plc (Nasdaq: CMPS), a biote
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom